All In Biotech

Drug Trial Radar · NCT05568797

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above

A Phase III, Open-label, Randomized, Controlled, Multi-country Study to Evaluate the Immune Response, Safety and Reactogenicity of an RSVPreF3 OA Investigational Vaccine When Co-administered With FLU aQIV (Inactivated Influenza Vaccine - Adjuvanted) in Adults Aged 65 Years and Above

Last checked: Nov 20, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,045 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,045

Actual

Start

Oct 14, 2022

Primary completion

Feb 17, 2023

Study completion Jul 17, 2023

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study is to assess the immunogenicity, safety and reactogenicity of the RSV PreFusion protein 3 older adult (RSVPreF3 OA) investigational vaccine when co-administered with an adjuvanted quadrivalent influenza (FLU aQIV) vaccine, in adults aged 65 years of age (YOA).

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • RSVPreF3 OA vaccineBiological

    One dose of RSVPreF3 OA vaccine administered intramuscularly.

  • FLU vaccineBiological

    One dose of FLU vaccine administered intramuscularly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Titers for Hemagglutination Inhibition (HI) Antibodies Against 4 FLU Vaccine Strains Expressed as Group Geometric Mean Titers (GMTs) at 1 Month After FLU Vaccine DoseTime frame: At 1 month after the FLU vaccine dose (Day 31 for both groups)
  2. RSV-A Neutralizing Antibody Titers Expressed as GMTsTime frame: At 1 month after the RSVPreF3 OA dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group)
  3. RSV-B Neutralizing Antibody Titers Expressed as GMTsTime frame: At 1 month after the RSVPreF3 OA dose (Day 31 for the CoAd Group and Day 61 for the Control Group)

Locations

37 sites in 5 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Edegem, Belgium

  • GSK Investigational Site

    Erpent, Belgium

  • GSK Investigational Site

    Genk, Belgium

  • GSK Investigational Site

    Ieper, Belgium

  • GSK Investigational Site

    Espoo, Finland

  • GSK Investigational Site

    Helsinki, Finland

  • GSK Investigational Site

    Kokkola, Finland

  • GSK Investigational Site

    Oulu, Finland

  • GSK Investigational Site

    Seinäjoki, Finland

  • GSK Investigational Site

    Tampere, Finland

  • GSK Investigational Site

    Angers, France

  • GSK Investigational Site

    Clermont-Ferrand, France

  • GSK Investigational Site

    Limoges, France

  • GSK Investigational Site

    Lyon, France

  • GSK Investigational Site

    Montpellier, France

  • GSK Investigational Site

    Nîmes, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Pierre-Bénite, France

  • GSK Investigational Site

    Benalmádena, Málaga, Spain

  • GSK Investigational Site

    Boadilla Del Monte (Madrid), Spain

  • GSK Investigational Site

    Burgos, Spain

  • GSK Investigational Site

    Centelles, Spain

  • GSK Investigational Site

    La Roca Del Valles (Barcelona), Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Salamanca, Spain

  • GSK Investigational Site

    Santander (Cantabria), Spain

  • GSK Investigational Site

    Valladolid, Spain

  • GSK Investigational Site

    Vic, Spain

  • GSK Investigational Site

    Marbella - Málaga, Andalusia, Spain

  • GSK Investigational Site

    Blackpool, United Kingdom

  • GSK Investigational Site

    Bristol, United Kingdom

  • GSK Investigational Site

    Chippenham, United Kingdom

  • GSK Investigational Site

    Peterborough, United Kingdom

  • GSK Investigational Site

    Soham, Cambridgeshire, United Kingdom

  • GSK Investigational Site

    Bollington, Cheshire, United Kingdom

  • GSK Investigational Site

    Chippenham, Wiltshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.